Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALT NASDAQ:CMRX NASDAQ:ORIC NASDAQ:ORPH NASDAQ:SESN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/ACMRXChimerix$8.54$8.54$0.75▼$8.55$801.09M-0.172.94 million shsN/AORICOric Pharmaceuticals$11.00+4.6%$10.43$3.90▼$14.67$1.07B1.631.09 million shs1.19 million shsORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shsSESNSesen Bio$10.50$0.37▼$12.58$2.56B0.831.07 million shs93,330 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%-0.50%CMRXChimerix0.00%0.00%0.00%0.00%+871.12%ORICOric Pharmaceuticals-3.49%0.00%+6.26%+14.10%+4.16%ORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%SESNSesen Bio0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/ACMRXChimerix$8.54$8.54$0.75▼$8.55$801.09M-0.172.94 million shsN/AORICOric Pharmaceuticals$11.00+4.6%$10.43$3.90▼$14.67$1.07B1.631.09 million shs1.19 million shsORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shsSESNSesen Bio$10.50$0.37▼$12.58$2.56B0.831.07 million shs93,330 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%-0.50%CMRXChimerix0.00%0.00%0.00%0.00%+871.12%ORICOric Pharmaceuticals-3.49%0.00%+6.26%+14.10%+4.16%ORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%SESNSesen Bio0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/ACMRXChimerix 2.00Hold$8.53-0.08% DownsideORICOric Pharmaceuticals 2.89Moderate Buy$17.2957.14% UpsideORPHOrphazyme A/S 0.00N/AN/AN/ASESNSesen Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ORPH, ORIC, CMRX, CALT, and SESN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025ORICOric PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.008/14/2025ORICOric PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$20.00 ➝ $17.008/14/2025ORICOric PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$22.00 ➝ $19.008/13/2025ORICOric PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/12/2025ORICOric PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/8/2025ORICOric PharmaceuticalsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.006/23/2025ORICOric PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$20.00(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74CMRXChimerix$212K3,778.71N/AN/A$2.17 per share3.94ORICOric PharmaceuticalsN/AN/AN/AN/A$3.45 per shareN/AORPHOrphazyme A/SN/AN/AN/AN/A$2.74 per shareN/ASESNSesen Bio$40M0.00N/A3.39$0.78 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/ACMRXChimerix-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%N/AORICOric Pharmaceuticals-$127.85M-$1.89N/AN/AN/AN/A-51.75%-47.09%11/11/2025 (Estimated)ORPHOrphazyme A/S-$97.01MN/A0.00N/AN/AN/AN/AN/AN/ASESNSesen Bio-$19.88M-$0.10N/AN/AN/AN/A6.70%5.41%N/ALatest ORPH, ORIC, CMRX, CALT, and SESN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ORICOric Pharmaceuticals-$0.46-$0.47-$0.01-$0.47N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/ACMRXChimerixN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/AORPHOrphazyme A/SN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALTCalliditas Therapeutics AB (publ)9.442.692.59CMRXChimerixN/A6.336.33ORICOric PharmaceuticalsN/A16.1316.13ORPHOrphazyme A/S0.141.80N/ASESNSesen BioN/A6.106.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALTCalliditas Therapeutics AB (publ)2.83%CMRXChimerix45.42%ORICOric Pharmaceuticals95.05%ORPHOrphazyme A/S10.74%SESNSesen Bio16.45%Insider OwnershipCompanyInsider OwnershipCALTCalliditas Therapeutics AB (publ)2.20%CMRXChimerix13.10%ORICOric Pharmaceuticals6.82%ORPHOrphazyme A/SN/ASESNSesen Bio3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableCMRXChimerix9093.80 million78.15 millionOptionableORICOric Pharmaceuticals8097.12 million90.50 millionOptionableORPHOrphazyme A/S14135.31 millionN/ANot OptionableSESNSesen Bio35203.49 million196.98 millionOptionableORPH, ORIC, CMRX, CALT, and SESN HeadlinesRecent News About These CompaniesTrey MewesApril 9, 2024 | startribune.comSDevin Haney: biography, record, fights and moreDecember 9, 2023 | espn.comTyson Fury: Biography, record, fights and moreDecember 2, 2023 | espn.comWhy the Tucker Carlson Biography Sales Are So PatheticSeptember 13, 2023 | thedailybeast.comTSesen Bio (NASDAQ: SESN)August 4, 2023 | fool.comJames McTeigue Biography & MoviesMay 10, 2023 | tribute.caTAfter revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen BioMarch 6, 2023 | bizjournals.comSesen Bio wins shareholder approval for Carisma mergerMarch 2, 2023 | msn.comSesen Bio Stockholders Approve Merger with Carisma TherapeuticsMarch 2, 2023 | finance.yahoo.comSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial ResultsFebruary 28, 2023 | finance.yahoo.comSHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing InvestigationsFebruary 24, 2023 | benzinga.comLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With CarismaFebruary 21, 2023 | finance.yahoo.comBML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsFebruary 17, 2023 | stockhouse.comLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special MeetingFebruary 16, 2023 | businesswire.comSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending MergerFebruary 16, 2023 | finance.yahoo.comSesen Bio reaches deal with investor group, paving way for Carisma mergerFebruary 15, 2023 | endpts.comELatest terms of Sesen Bio and Carisma merger appear to pass musterFebruary 15, 2023 | thepharmaletter.comT5 big dividend moves: Group 1 Automotive hikes by 20% | Pro RecapFebruary 15, 2023 | finance.yahoo.comBML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsFebruary 15, 2023 | finance.yahoo.comSesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor groupFebruary 14, 2023 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesEqual Weight ETFs: Hidden Upside in Today’s MarketBy Gabriel Osorio-Mazilli | August 23, 2025Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick?By Chris Markoch | August 28, 2025Gold’s Explosive Rally: GDX ETF May Be the Fast Track to ProfitsBy Jeffrey Neal Johnson | September 4, 2025MarketBeat Week in Review – 08/18 - 08/22By MarketBeat Staff | August 23, 2025General Mills Is a Generational Opportunity for Income InvestorsBy Thomas Hughes | September 18, 2025ORPH, ORIC, CMRX, CALT, and SESN Company DescriptionsCalliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 09/17/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Chimerix NASDAQ:CMRXChimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Oric Pharmaceuticals NASDAQ:ORIC$11.00 +0.48 (+4.56%) Closing price 04:00 PM EasternExtended Trading$10.98 -0.02 (-0.14%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Orphazyme A/S NASDAQ:ORPHOrphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.Sesen Bio NASDAQ:SESNSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
